SCHEMBL127604

SCHEMBL127604

CCCCc1c(-c2ccc(OC)c(OC3CC3)c2)[nH]c2cn[nH]c(=O)c12

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 11/20 0.39
PDE4B Q07343 10/20 0.39
PDE4C Q08493 10/20 0.39
PDE4D Q08499 10/20 0.39
MAPK1 P28482 2/20 0.38
LMNA P02545 1/20 0.38
TLR8 Q9NR97 4/20 0.37
TLR7 Q9NYK1 4/20 0.37
TLR9 Q9NR96 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131447 0.91 PDE4D (0.37) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL128067 0.88 PDE4D (0.36) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL130411 0.88 PDE4D (0.36) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL129424 0.86 PDE4D (0.39) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL127495 0.82 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL127418 0.82 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL128403 0.82 PDE4A (0.36) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL129016 0.81 KCNH2 (0.40) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL130306 0.81 PDE4D (0.35) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL128370 0.80 PDE4D (0.37) PDE4APDE4BPDE4CPDE4DMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US claimed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP claimed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US claimed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP claimed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 PDE4A 3035/4885PDE4B 3261/4885PDE4C 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.